Gastro-esophageal Reflux Disease (GERD) Completed Phase 4 Trials for Lansoprazole (DB00448)

Also known as: Gastroesophageal Reflux Disease / Gastro-esophageal Reflux Disease / GERD / GERD Gastroesophageal Reflux Disease / Gastro-Oesophageal Reflux Disease / Gastrooesophageal reflux disease / GERD (Gastroesophageal Reflux Disease) / Esophageal Reflux / GERD - Gastro-Esophageal Reflux Disease / Gastroesophageal Reflux Disease (GERD) / Gastro-esophageal Reflux Diseases / Oesophageal reflux / Esophagitis / Gastrooesophageal reflux / Gastroesophageal reflux / Esophageal reflux NOS

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02958046The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal AcidityTreatment
NCT00410592Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERDTreatment
NCT00637845Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)Treatment